Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эрадикационная терапия Helicobacter pylori: современные тенденции
Эрадикационная терапия Helicobacter pylori: современные тенденции
Н.Н.Дехнич. Эрадикационная терапия Helicobacter pylori: современные тенденции. Consilium Medicum. Гастроэнтерология (Прил.). 2013; 1: 10-13.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Warren JR, Marshal B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273–5.
2. Kuipers EJ. Helicobacter pylori, MALT lymphoma and gastric cancer. J Chemther 1999; 11 (20): 25–8.
3. Megraud F, Coenen S, Versporten A et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008–2009. Ther Adv Gastroenterol 2012; 5 (2): 103–9.
4. Aqudo S, Perez-Perez G, Lopez-Brea M. High prevalence of clarithromycin resistance Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48 (10): 3703–7.
5. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155–68.
6. Malfertheiner P, Megraud F, O’Morain C at al. Management of Helicobacter pylori infection – Maastricht IV / Florence consensus report. Gut 2012; 61: 646–64.
7. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012; 1: 87–9.
8. Szajewska H еt al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol & Therapeutics 2010; 32 (9): 1069–79.
9. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
10. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
11. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
12. Duman DG, Bor S, Ozütemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
13. Song MJ, Park DI, Park JH et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15 (3): 206–13.
14. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
15. Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 2005; 94: 1747–51.
16. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterol 1994; 107 (6): 1671–4.
17. Falsafi T, Valizadeh N, Najafi M et al. Culture of Helicobacter pylori from stool samples in children. Can J Microbiol 2007; 53 (3): 411–6.
18. Topping DI, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological Rev 2001; 81 (3): 1031–64.
2. Kuipers EJ. Helicobacter pylori, MALT lymphoma and gastric cancer. J Chemther 1999; 11 (20): 25–8.
3. Megraud F, Coenen S, Versporten A et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008–2009. Ther Adv Gastroenterol 2012; 5 (2): 103–9.
4. Aqudo S, Perez-Perez G, Lopez-Brea M. High prevalence of clarithromycin resistance Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48 (10): 3703–7.
5. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155–68.
6. Malfertheiner P, Megraud F, O’Morain C at al. Management of Helicobacter pylori infection – Maastricht IV / Florence consensus report. Gut 2012; 61: 646–64.
7. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012; 1: 87–9.
8. Szajewska H еt al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol & Therapeutics 2010; 32 (9): 1069–79.
9. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
10. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
11. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
12. Duman DG, Bor S, Ozütemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
13. Song MJ, Park DI, Park JH et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15 (3): 206–13.
14. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
15. Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 2005; 94: 1747–51.
16. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterol 1994; 107 (6): 1671–4.
17. Falsafi T, Valizadeh N, Najafi M et al. Culture of Helicobacter pylori from stool samples in children. Can J Microbiol 2007; 53 (3): 411–6.
18. Topping DI, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological Rev 2001; 81 (3): 1031–64.
Авторы
Н.Н.Дехнич
Кафедра факультетской терапии ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ
Кафедра факультетской терапии ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.